SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the impact of a recent purchase of TSLA stock by Elon Musk, with some seeing it as a positive signal and others suspecting market manipulation. Concerns about global sales figures and increasing competition in the EV sector are also being discussed alongside speculation about future ventures like AI and robotics. The stock's volatile price action is fueling both bullish and bearish sentiment, with traders closely watching key technical levels.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its Bitcoin-native meme coin status, emphasizing its decentralized and community-driven nature. Discussions highlight its fair launch and fixed supply, contrasting it with other meme coins and positioning it as a long-term play within the Bitcoin ecosystem. Some also point to corporate treasury activity as a potential catalyst.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around recent dips, viewing them as buying opportunities before upcoming utility releases. The community is actively discussing strategies to push the coin to new ATHs, fueled by bullish sentiment and a strong belief in the project's long-term potential. Community members are anticipating a potential airdrop at the 5 million MC milestone.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to volatility following its merger, with a potential share offering sparking debate about dilution and short squeeze opportunities. The community is closely watching short interest, cost to borrow, and potential for a squeeze, while also discussing technical analysis and potential catalysts like Bitcoin purchases. Trading restrictions on some platforms due to the CUSIP change may also be affecting price action.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as community members discuss its potential role in powering AI data centers and strategic uranium reserves. Bullish sentiment is fueled by the company's innovative approach to nuclear energy, while others express concerns about its current valuation and lack of revenue. Traders are actively debating entry and exit points as the stock experiences volatility.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending following news of a licensing agreement with Novartis, potentially worth billions, for developing molecular glue degraders. The community is actively discussing the implications of the deal, including potential milestone payments and royalties, with some speculating about a possible buyout. Bullish investors express confidence in the stock's long-term potential, citing the company's strong cash position and innovative platform, while others are wary of short-term volatility.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility as traders discuss a recent partnership announcement focused on Solana cryptocurrency. Community members are pointing to unusual volume and potential short squeezes, while also debating the merits of the company's new crypto strategy and upcoming catalysts. The stock is garnering attention as a low float runner and potential pump and dump, with some traders citing technical indicators and prior price action.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community discusses JD Vance's appearance on the platform and the potential impact of Rumble's ties to crypto, including Tether's ownership stake and the upcoming Rumble Wallet. High short interest is also fueling speculation about a potential squeeze. Some users remain skeptical about Rumble's business model and profitability.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as conversations revolve around the potential for government contracts and its strategic positioning in uranium and rare earth elements. Community members are actively discussing the company's dual narrative and debating whether it is currently undervalued. The stock's movement is also influenced by broader trends in the uranium sector and discussions around energy independence.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors eye potential new all-time highs, with the stock exhibiting strength despite recent market volatility. Community members are actively discussing technical indicators, options activity, and the potential impact of Uber's inclusion in the S&P 100. Positive analyst ratings and long-term growth prospects in mobility and delivery are also fueling bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

Equity

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.


TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

 Company News for Aug 5, 2025

TG Therapeutics, Inc. (TGTX) on Monday reaffirmed confidence in its flagship drug Briumvi despite a disappointing second-quarter earnings report.Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.“With multiple growth drivers in place, expanding patient and prescriber bases, increasing brand recognition and the momentum of our media investments, we believe Briumvi is on track to become a multibillion-dollar brand in relapsing MS,” said Adam Waldman, Chief Commercial Officer at TG Therapeutics, on the company’s earnings call while adding that it expects stronger growth from the third quarter (Q3) to the fourth quarter (Q4).The firm also raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. TG Therapeutics is also evaluating Briumvi in the treatment of Myasthenia Gravis and testing subcutaneous Briumvi, allowing self-administration of the drug.The company now sees a total global revenue target of approximately $585 million for the full year 2025, up from its previous guidance of $575 million.&nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1336/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_1_21_31_PM_png_bda23ffe5e.webp" alt="TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="1336" height="132"><figcaption>TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>TGTX stock slid over 16% on Monday following the downbeat earnings. A Stocktwits user believes the drop in stock following the earnings report is an opportunity to buy more.<stembedurl>https://stocktwits.com/Firstcall/message/623650797</stembedurl>Another opined that the drop is not justifiable, given that the company raised its guidance.<stembedurl>https://stocktwits.com/Firstcall/message/623647493</stembedurl>For the second quarter, the company’s total revenue came in at $141.15 million, compared to $73.47 million in the corresponding quarter of 2024, and below an analyst estimate of $147.76 million. Briumvi’s net product revenue alone came in at $138.8 million, representing 91% growth over the same period last year, and accounting for over 98% of the company’s total revenue.Diluted earnings per share came in at $0.17, above the $0.04 reported in Q2 2024, but below an analyst estimate of $0.25.&nbsp;TGTX stock is down by 3% this year but up by 70% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-rivian-to-report-q2-earnings-tomorrow/chrXpf7RdTz">Lucid, Rivian To Report Q2 Earnings Tomorrow: Retail Watches Warily With Mixed Sentiments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.


TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTX TG Therapeutics Inc